August 2, 2006Cardiovascular Research
Hypoxia- and non-hypoxia-related pulmonary hypertension — Established and new therapies
Key result
This review provides an update on the pathophysiology and currently available therapeutic options for hypoxia- and non-hypoxia-related pulmonary hypertension.
Population
Patients with hypoxia- and non-hypoxia-related pulmonary hypertension (excluding pulmonary venous congestion)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Highlights risks of non-selective vasodilators in hypoxemic PH; leaves open targeted therapy trials.
Structured PICO
P
Population
Patients with hypoxia- and non-hypoxia-related pulmonary hypertension (excluding pulmonary venous congestion)
I
Intervention
Specific therapies for pulmonary hypertension (prostanoids, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors)
This review provides an update on the pathophysiology and therapeutic options for hypoxia- and non-hypoxia-related pulmonary hypertension, highlighting the risks of non-selective vasodilators in hypoxemic patients.
Cite This Study
Ghofrani et al. (2006) conducted a review in Pulmonary hypertension. Therapies for pulmonary hypertension (prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors) was evaluated. This review provides an update on the pathophysiology and currently available therapeutic options for hypoxia- and non-hypoxia-related pulmonary hypertension.